Protalix Biotherapeutics Inc (PLX) Stock Rating Reaffirmed by HC Wainwright
Protalix Biotherapeutics Inc (NYSEMKT:PLX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Thursday. They presently have a $5.00 price objective on the stock.
Separately, Zacks Investment Research downgraded Protalix Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th.
Protalix Biotherapeutics (NYSEMKT:PLX) opened at $0.69 on Thursday. Protalix Biotherapeutics has a twelve month low of $0.26 and a twelve month high of $1.51.
Protalix Biotherapeutics (NYSEMKT:PLX) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.04). The firm had revenue of $7.53 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same period in the previous year, the firm earned ($0.07) EPS.
Several institutional investors have recently added to or reduced their stakes in PLX. Renaissance Technologies LLC boosted its position in shares of Protalix Biotherapeutics by 302.1% during the first quarter. Renaissance Technologies LLC now owns 1,927,500 shares of the company’s stock valued at $2,621,000 after buying an additional 1,448,200 shares during the last quarter. Virtu KCG Holdings LLC purchased a new stake in shares of Protalix Biotherapeutics during the second quarter valued at $591,000. OxFORD Asset Management LLP purchased a new stake in shares of Protalix Biotherapeutics during the second quarter valued at $576,000. Finally, Wells Fargo & Company MN boosted its position in shares of Protalix Biotherapeutics by 14,285.7% during the first quarter. Wells Fargo & Company MN now owns 100,700 shares of the company’s stock valued at $137,000 after buying an additional 100,000 shares during the last quarter.
Protalix Biotherapeutics Company Profile
Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action.
Receive News & Ratings for Protalix Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.